Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The prognostic significance of macrophage and natural killer (NK) cell infiltration in colorectal carcinoma (CRC) microenvironment is unclear. We investigated the CRC innate inflammatory infiltrate in over 1,600 CRC using two independent tissue microarrays and immunohistochemistry. Survival time was assessed using the Kaplan–Meier method and Cox proportional hazards regression analysis in a multivariable setting. Spearman's rank correlation tested the association between macrophage and lymphocyte infiltration. The Basel study included over 1,400 CRCs. The level of CD16+ cell infiltration correlated with that of CD3+ and CD8+ lymphocytes but not with NK cell infiltration. Patients with high CD16+ cell infiltration (score 2) survived longer than patients with low (score 1) infiltration (p = 0.008), while no survival difference between patients with score 1 or 2 for CD56+ (p = 0.264) or CD57+ cell (p = 0.583) infiltration was detected. CD16+ infiltrate was associated with improved survival even after adjusting for known prognostic factors including pT, pN, grade, vascular invasion, tumor growth and age [(p = 0.001: HR (95% CI) = 0.71 (0.6–0.9)]. These effects were independent from CD8+ lymphocyte infiltration [(p = 0.036: HR (95% CI) = 0.81 (0.7–0.9)] and presence of metastases [(p = 0.002: HR (95% CI) = 0.43 (0.3–0.7)]. Phenotypic studies identified CD16+ as CD45+CD33+CD11b+CD11c+ but CD64− HLA‐DR‐myeloid cells. Beneficial effects of CD16+ cell infiltration were independently validated by a study carried out at the University of Athens confirming that patients with CD16 score 2 survived longer than patients with score 1 CRCs (p = 0.011). Thus, CD16+ cell infiltration represents a novel favorable prognostic factor in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“Discussion There is substantial evidence that adaptive immune response is able to counteract CRC progression.(3,5) However, the role played by the innate immune system in this process is still controversial.”
BackgroundBingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156 · cited 1×
“Therapeutic monoclonal antibodies (mAbs) are also widely used, but indications for their administration still need to be fully clarified.(2) The identification of biological markers of potential prognostic significance, allowing correct stratification of CRC patients and helping in the selection of therapeutic options…”
BackgroundThe inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
Cited by
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., Zlobec, I., Eppenberger-Castori, S., Tzankov, A., Rosso, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.015 · Cited by 431
Self-citationThe Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
CAR-T cells: the long and winding road to solid tumors
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0278-6 · Cited by 399
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Gut microbiota modulate T cell trafficking into human colorectal cancer
Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275
Self-citationLi, Y., Liang, L., Dai, W., Cai, G., Xu, Y., Li, X., Li, Q., & Cai, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0539-x · Cited by 270
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Lapteva, N., Durett, A. G., Sun, J., Rollins, L. A., Huye, L. L., Fang, J., Dandekar, V., Mei, Z., Jackson, K., Vera, J., et al. (2012) · Cytotherapy · doi:10.3109/14653249.2012.700767 · Cited by 216
Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer
Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310016 · Cited by 189
Self-citation
Metadata
- Authors
- Sconocchia, G., Zlobec, I., Lugli, A., Calabrese, D., Iezzi, G., Karamitopoulou, E., Patsouris, E. S., Peros, G., Horcic, M., Tornillo, L., Zuber, M., Droeser, R., Muraro, M. G., Mengus, C., Oertli, D., Ferrone, S., Terracciano, L., & Spagnoli, G. C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-10-13
- Volume
- 128
- Issue
- 11
- Pages
- 2663-2672
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2135202266
- Cited by
- 112
- References
- 5
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.